

ASX RELEASE

9 January 2017

Results of General Meeting

MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or the "Company") today held a General Meeting at the Offices of BDO, 38 Station Street, Subiaco WA 6008.

All resolutions were passed on a show of hands.

In accordance with section 251AA of the Corporations Act, proxy votes exercisable by all proxies validly appointed were;

Resolution	For	Discretionary	Against	Abstain
1. Approval to Dispose of a Main Undertaking	14,568,040	736,406	1,579,271	88,641
2. Approval to Dispose of a Major Asset Without Pro Rata Offer to Shareholders	13,966,679	782,095	1,895,777	327,807

For more information please contact

Erlyn Dale

Company Secretary

+61 8 9389 3150

info@mmjphytotech.com.au

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX: MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

The Company is currently in the process of finalising a transaction with Canadian-based Harvest One Capital Corp. ("Harvest One") (TSXV NEX: WON.H) for the listing of the MMJ's core cannabis subsidiaries on the TSX-V via the reverse takeover of Harvest One.

United Greeneries Holding Ltd. has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

ASX RELEASE

The Company's European, cannabis-based, pharmaceutical, nutraceutical and cosmetics division operates under its 100% owned subsidiary, **Satipharm AG**. MMJ began production of its Gelpell® Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.

MMJ's Israel-based subsidiary, **PhytoTech Therapeutics Ltd**, is responsible for the Company's R&D activities, with a key focus on the development and commercialisation of new and existing delivery systems and devices that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients.